Ulcerative Colitis

Entyvio and Stelara were commonly used in combination therapy for the treatment of inflammatory bowel disease, according to research at Digestive Disease Week.

Abivax announced positive phase 2b clinical induction and results for ABX464 in the treatment of patients with moderate to severe ulcerative colitis, according to a press release.

There was a 15-fold increase of venous thromboembolism among the pediatric inflammatory bowel disease population compared with the general population, according to presenter at Digestive Disease Week.

The FDA has approved Zeposia 0.92 mg for the treatment of moderate-to-severe ulcerative colitis.

Selective janus kinase 1 inhibitor, SHR0302, induced clinical response and remission among patients with moderate to severe ulcerative colitis, according to a study at Digestive Disease Week.

Increased consumption of processed foods correlated with the development of inflammatory bowel disease, according to a presentation at Digestive Disease Week.

Rising rates of ultra-processed food consumption correlated with an increased risk for Crohn’s disease, according to a presentation at Digestive Disease Week.

Alcohol use disorder correlated with a higher risk for in-hospital mortality among patients with inflammatory bowel disease, according to a presentation at Digestive Disease Week.

Crohn’s disease and ulcerative colitis disproportionately affected non-Hispanic white patients, according to research presented at Digestive Disease Week.

Discontinued long-term use of infliximab correlated with lower rates of maintained remission in patients with ulcerative colitis, according to research published in The Lancet Gastroenterology and Hepatology.